IPN, Delhi, India. Open 10-6pm

+91 9891296838 / 9811747774

List of Oncology Medication For

Blood Disorders

Indian Pharma Network

M: +9891296838 / 9811747774
E: med@indianpharmanetwork.co.in

Bortezomib for Injection

Bortezomib Injection
for subcutaneous use Initial U.S. Approval: 2003

bortezomib is a proteasome inhibitor indicated for:
• treatment of patients with multiple myeloma
• treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.

Facts about Bortezomib for Injection

Approval Date: 2003
Proprietary Name: On Request
Active Ingredient(s): Bortezomib for Injection
Dosage Forms And Strengths:
Manufacturer:
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “Bortezomib for Injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

read more

bosutinib tablets

bosutinib tablets
for oral use Initial U.S. Approval: XXXX

Bosulif (bosutinib) is a medication used for the treatment of chronic myeloid leukaemia (CML) in adults with the Philadelphia chromosome (Ph+). It is used to treat adult patients with newly-diagnosed chronic phase Ph+ chronic myelogenous leukemia (CML) or with chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.

Facts about bosutinib-tablets

DISEASE INDICATIONS-Leukemia
MANUFACTURER-Pfizer Limited
USAGE-Tablets: 100 mg and 500 mg
MEDICINE APPROVED BY-European Medical Agency (EMA),Food and Drug Administration (FDA)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “sotorasib tablets” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

read more

calaspargase pegol-mknl injection

calaspargase pegol -mknl injection
for intravenous use Initial U.S. Approval: 2018

Asparlas (calaspargase pegol-mknl) is a component of a multiagent chemotherapeutic regimen for the treatment of Acute Lymphoblastic Leukemia (ALL) in pediatric and young adult patients aged 1 month to 21 years.

Facts about calaspargase pegol -mknl injection

DISEASE INDICATIONS-Leukemia
MANUFACTURER-Servier
USAGE-Intravenous
MEDICINE APPROVED BY-Food and Drug Administration (FDA)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “sotorasib tablets” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

read more

carfilzomib for Injection

carfilzomib for Injection
for intravenous use Initial U.S. Approval: 2012

Carfilzomib injection is used alone and in combination with other medications to treat people with multiple myeloma (a type of cancer of the bone marrow) who have already been treated with other medications. Carfilzomib is in a class of medications called proteasome inhibitors.

Facts about carfilzomib for Injection

Approval Date: 2012
Proprietary Name: On Request
Active Ingredient(s): carfilzomib for Injection
Dosage Forms And Strengths: Single-use vial: 60 mg sterile lyophilized powder
Current indications: multiple myeloma
Medicine Approved By: –
 European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “carfilzomib for Injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

read more

COTELLIC (cobimetinib) Tablets

The Cotellic specifically contains the active substance Cobimetinib. The cobimetinib 20 mg specifically belongs to the kinase inhibitors class of drug. Falls under the kinase inhibitor class of drug, cobimetinib acts in order to block the action of an abnormal protein that signals cancer cells to multiply. This helps resist or block the spread of cancerous cells.

Brand Name: Cotellic
Innovator Brand Name: Cotellic
API: Cobimetinib Fumarate
Packaging: 63 Tablets
Strength: 20mg
Manufacturer Name: Genentech

Access Patient Name Basis Treatment

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import COTELLIC (cobimetinib) Tablets ” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

read more

Dactinomycin Injection

dactinomycin for injection
for intravenous use Initial U.S. Approval: 1964

dactinomycin for injection as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Facts about Dactinomycin Injection

Approval Date: 1964
Proprietary Name: On Request
Active Ingredient(s): Dactinomycin Injection
Dosage Forms And Strengths: For injection: 500 mcg as a lyophilized powder in a single-dose vial. 
Manufacturer:
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “Dactinomycin Injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

read more

daratumumab injection

daratumumab injection
for intravenous use Initial U.S. Approval

Darzalex (daratumumab) is a human CD38-directed monoclonal antibody used to treat multiple myeloma.

Facts about daratumumab injection

DISEASE INDICATIONS-Multiple Myeloma
MANUFACTURER-Janssen-Cilag International N.V.
USAGE-Intravenous
MEDICINE APPROVED BY-European Medical Agency (EMA),Food and Drug Administration (FDA),Health Canada,Therapeutic Goods Administration (TGA),Medsafe (NZ)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “daratumumab injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

read more

Dasatinib Tablets

dasatinib Tablet
for Oral Use Initial U.S. Approval: 2006

SPRYCEL is a kinase inhibitor indicated for the treatment of • newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.

Facts about Dasatinib Tablets

Approval Date: 2006
Proprietary Name: On Request
Active Ingredient(s): Dasatinib Tablets
Dosage Forms And Strengths: Tablets: 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg.
Company: Bristol-Myers Squibb
Current indications: chronic Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)
Medicine Approved By: –
 European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “Dasatinib Tablets” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

read more

Daunorubicin and cytarabine liposome injection

Daunorubicin and cytarabine liposome injection
for subcutaneous use Initial U.S. Approval: 2017

Daunorubicin and cytarabine  is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor, that is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Facts about Daunorubicin and cytarabine liposome injection

Approval Date: 2017
Proprietary Name: On Request
Active Ingredient(s): Daunorubicin and cytarabine liposome injection
Dosage Forms And Strengths:
Manufacturer:
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “Daunorubicin and cytarabine liposome injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

read more

decitabine and cedazuridine tablets

decitabine and cedazuridine tablets,
for oral use Initial U.S. Approval: 2020

Inqovi (decitabine and cedazuridine) is a medication used for the treatment of adults with myelodysplastic syndromes (MDS), including chronic myelomonocytic leukemia (CMML).

Facts about decitabine and cedazuridine tablets

Disease Indications-Leukemia
Manufacturer-Astex Pharmaceuticals
Usage-Intravenous
Medicine Approved By-Food and Drug Administration (FDA), Health Canada
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “decitabine and cedazuridine tablets” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

read more

Contact Info

CORPORATE OFFICE:
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.

MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398

EMAIL ID:
info@indianpharmanetwork.co.in

FAX NUMBER:
+91-11-26532129

Query Form For Medications

Indian Pharma Network (IPN), New Delhi. India

Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa

Indian Pharma Network
60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016

Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398